The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Vertex Ends Work on One Hepatitis Drug, Continues Another

September 26, 2012

Vertex Pharmaceuticals announced the discontinuation of work on the experimental hepatitis C drug ALS-2158 and resumption of development on another hepatitis C drug, ALS-2200. ALS-2158, which was being developed with partner Alios BioPharma Inc., did not show enough efficacy. On the other hand, ALS2200 showed promise in an early trial. The company is planning a mid-stage or Phase II trial of ALS-2200 in combination with ribavirin and one trial to evaluate ALS-220 in combination with the existing drug Incivek. Incivek, which must be taken with interferon, was approved in 2011 and so far has doubled the cure rate of prior standard treatments.

View Full Article

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: